Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brodalumab for Immune-Related Adverse Events in Solid Tumors
NCT06673329Phase 1Recruiting
- Start
- Mar 2025
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of brodalumab in immune-related adverse event (irAE). Primary endpoints: Number of Adverse Events at 36 weeks and Percentage of primary Immune-Related Adverse Event (irAE) severity decreased at 24 weeks. Started Mar 2025; status: recruiting.
02
Drugs
brodalumab
03
Conditions
immune-related adverse event (irAE)
Beyond the preview
Go deeper on NCT06673329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06673329.